RapidPulse Raises Funding for Ischemic Stroke Therapies

September 13, 2022—RapidPulse, Inc., a privately held medical device company, announced that it has raised an additional $10.5 million, bringing its cumulative financing to over $25 million.

According to RapidPulse, the proceeds will be used to further advance the RapidPulse Cyclic aspiration system through expanded clinical evaluation, which in turn will further the development of its platform of new catheters and aspiration pump, and to move towards FDA approval. The device is designed to allow rapid and consistent removal of blood clots from the brain. It is not available for sale and continues to be tested and evaluated through investigational studies.

The financing was led by Syntheon and Santé Ventures who were joined by Epidarex Capital, Hatteras Venture Partners, and Broadview Ventures.

RapidPulse is a spinout of Syntheon 2.0, LLC., a medical device incubator. Sean McBrayer serves as the CEO of RapidPulse as well as CEO of Syntheon.

In the company’s press release, Mr. McBrayer commented, “RapidPulse has built an excellent team and taken great strides in developing our technology and system architecture; we’ve had three seminal patents issued to protect our intellectual property and we’ve received excellent feedback from some of the leading ischemic stroke physicians.”

He stated further, “In addition, our early clinical results have been outstanding. As disclosed at a recent industry conference, initial testing of our technology has shown first pass clot removal of up to 69% of the time, a dramatic improvement over standard aspiration. We are also particularly pleased and gratified that our established investor syndicate was enthusiastic about increasing the company’s funding to build on our progress.”

The pilot study to which Mr. McBrayer referred included 29 patients with reported first-pass success using mTICI (modified treatment in cerebral infarction) score ≥ 2c, noted the company.